Hospital merger and acquisition activity ended 2025 with momentum expected to continue as drastic cuts to Medicaid spending under Trump’s One Big Beautiful Bill Act loom.
Tag: policy
-
FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation
The U.S. Food and Drug Administration today announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing and control (CMC) requirements for cell and gene therapies (CGT).